参考文献/References:
[1] SUNG H,FERLAY J,SIEGEL R L,et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA: A Cancer Journal for Clinicians,2021,71(3):209-249.DOI:10.3322/caac.21660.
[2] GANESAN P,KULIK L M.Hepatocellular carcinoma[J].Clinics in Liver Disease,2023,27(1):85-102.DOI:10.1016/j.cld.2022.08.004.
[3] VOGEL A,MEYER T,SAPISOCHIN G,et al.Hepatocellular carcinoma[J].Lancet,2022,400(10360):1345-1362.DOI:10.1016/S0140-6736(22)01200-4.
[4] AMIN M B,GREENE F L,EDGE S B,et al.The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more ″personalized″ approach to cancer staging[J].CA: A Cancer Journal for Clinicians,2017,67(2):93-99.DOI:10.3322/caac.21388.
[5] REIG M,FORNER A,RIMOLA J,et al.BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update[J].Journal of Hepatology,2022,76(3):681-693.DOI:10.1016/j.jhep.2021.11.018.
[6] AJOOLABADY A,TANG D,KROEMER G,et al.Ferroptosis in hepatocellular carcinoma: Mechanisms and targeted therapy[J].British Journal of Cancer,2023,128(2):190-205.DOI:10.1038/s41416-022-01998-x.
[7] HUANG Ziyue,XIA Haoming,CUI Yunfu,et al.Ferroptosis: From basic research to clinical therapeutics in hepatocellular carcinoma[J].Journal of Clinical and Translational Hepatology,2023,11(1):207-218.DOI:10.14218/JCTH.2022.00255.
[8] TANG Daolin,KROEMER G,KANG Rui.Ferroptosis in hepatocellular carcinoma: From bench to bedside[J].Hepatology,2023,11(1):207-218.DOI:10.1097/HEP.0000000000000390.
[9] YANG Fan,XIAO Yi,DING Jiahan,et al.Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy[J].Cell Metabolism,2023,35(1):84-100.DOI:10.1016/j.cmet.2022.09.021.
[10] CHENG Zhe,CHEN Yongheng,HUANG Huichao.Identification and validation of a novel prognostic signature based on ferroptosis-related genes in ovarian cancer[J].Vaccines,2023,11(2):205-225.DOI:10.3390/vaccines11020205.
[11] YUAN Hua,LI Xuemei,ZHANG Xiuying,et al.CISD1 inhibits ferroptosis by protection against mitochondrial lipid peroxidation[J].Biochemical and Biophysical Research Communications,2016,478(2):838-844.DOI:10.1016/j.bbrc.2016.08.034.
[12] JENNIS M,KUNG C P,BASU S,et al.An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model[J].Genes & Development,2016,30(8):918-930.DOI:10.1101/gad.275891.115.
[13] CHANG K,CHEN Y,ZHANG X,et al.DPP9 Stabilizes NRF2 to suppress ferroptosis and induce sorafenib resistance in clear cell renal cell carcinoma[J].Cancer Research,2023,83(23):3940-3955.DOI:10.1158/0008-5472.
[14] CAI Mengxing,LUO Jingwen,YANG Chunxiu,et al.ABHD12 contributes to tumorigenesis and sorafenib resistance by preventing ferroptosis in hepatocellular carcinoma[J].iScience,2023,26(12):108340-108358.DOI:10.1016/j.isci.2023.108340.
[15] SUN Xiaofang,NIU Xiaohua,CHEN Ruochan,et al.Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis[J].Hepatology,2016,64(2):488-500.DOI:10.1002/hep.28574.
[16] THOMSON D W,DINGER M E.Endogenous microRNA sponges: Evidence and controversy[J].Nature Reviews Genetics,2016,17(5):272-283.DOI:10.1038/nrg.2016.20.
[17] SHI Yi,LIU Jibin,DENG Jing,et al.The role of ceRNA-mediated diagnosis and therapy in hepatocellular carcinoma[J].Hereditas,2021,158(1):44-58.DOI:10.1186/s41065-021-00208-7.
[18] ZHANG Ying,LUO Meiying,CUI Xiaohong,et al.Long noncoding RNA NEAT1 promotes ferroptosis by modulating the miR-362-3p/MIOX axis as a ceRNA[J].Cell Death and Differentiation,2022,29(9):1850-1863.DOI:10.1038/s41418-022-00970-9.
[19] YANG Zelong,HE Kun,CHEN Weigang,et al.A ferroptosis-related ceRNA network in hepatocellular carcinoma for potential clinical applications[J].American Journal of Translational Research,2023,15(6):3912-3927.
[20] CHEN Xin,LI Jingbo,KANG Rui,et al.Ferroptosis: Machinery and regulation[J].Autophagy,2021,17(9):2054-2081.DOI:10.1080/15548627.2020.1810918.
[21] TANG Daolin,CHEN Xin,KANG Rui,et al.Ferroptosis: Molecular mechanisms and health implications[J].Cell Research,2021,31(2):107-125.DOI:10.1038/s41422-020-00441-1.
[22] LIU Jiankun,LIU Zhiyong,LI Wei,et al.SOCS2 is a potential prognostic marker that suppresses the viability of hepatocellular carcinoma cells[J].Oncology Letters,2021,21(5):399-409.DOI:10.3892/ol.2021.12660.
[23] CHEN Qianping,ZHENG Wang,GUAN Jian,et al.SOCS2-enhanced ubiquitination of SLC7A11 promotes ferroptosis and radiosensitization in hepatocellular carcinoma[J].Cell Death & Differentiation,2022,30(1):137-151.DOI:10.1038/s41418-022-01051-7.
[24] AU S L K,WONG C C L,LEE J M F,et al.Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis[J].Hepatology,2012,56(2):622-631.DOI:10.1002/hep.25679.
[25] WANG Bohan,LIU Yachong,LIAO Zhibin,et al.EZH2 in hepatocellular carcinoma: Progression, immunity, and potential targeting therapies[J].Experimental Hematology & Oncology,2023,12(1):52-65.DOI:10.1186/s40164-023-00405-2.
[26] SHIN C S,MISHRA P,WATROUS J D,et al.The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility[J].Nature Communications,2017,21(8):15074-15085.DOI:10.1038/ncomms15074.
[27] HE Feng,ZHANG Peng,LIU Junlai,et al.ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11(xCT)to block stress-related ferroptosis[J].Journal of Hepatology,2023,79(2):362-377.DOI:10.1016/j.jhep.2023.03.016.
[28] Lü Ning,ZENG Yan,KONG Yanan,et al.Ferroptosis is involved in the progression of hepatocellular carcinoma through the circ0097009/miR-1261/SLC7A11 axis[J].Annals of Translational Medicine,2021,9(8):675-686.DOI:10.21037/atm-21-997.
[29] DIMRI M,HUMPHRIES A,LAKNAUR A,et al.NAD(P)H quinone dehydrogenase 1 ablation inhibits activation of the phosphoinositide 3-kinase/Akt serine/threonine kinase and mitogen-activated protein kinase/extracellular signal-regulated kinase pathways and blocks metabolic adaptation in hepatocellular carcinoma[J].Hepatology,2020,71(2):549-568.DOI:10.1002/hep.30818.
[30] QIN Xianyang,SU Ting,YU Wenkui,et al.Lipid desaturation-associated endoplasmic reticulum stress regulates MYCN gene expression in hepatocellular carcinoma cells[J].Cell Death & Disease,2020,11(1):66-79.DOI:10.1038/s41419-020-2257-y.
[31] YASUKAWA K,LIEW L C,HAGIWARA K,et al.MicroRNA-493-5p-mediated repression of the MYCN oncogene inhibits hepatic cancer cell growth and invasion[J].Cancer Science,2020,111(3):869-880.DOI:10.1111/cas.14292.
[32] LIU Chunjiang,TANG Liming,XU Miaojun,et al.LncRNA RUSC1-AS1 contributes to the progression of hepatocellular carcinoma cells by modulating miR-340-5p/CREB1 axis[J].American Journal of Translational Research,2021,13(3):1022-1036.
[33] LI Zhixi,WU Gang,LI Jie,et al.lncRNA CRNDE promotes the proliferation and metastasis by acting as sponge miR-539-5p to regulate POU2F1 expression in HCC[J].BMC Cancer,2020,20(1):282-293.DOI:10.1186/s12885-020-06771-y.
[34] WEI Huamei,XU Zuoming,CHEN Liucui,et al.Long non-coding RNA PAARH promotes hepatocellular carcinoma progression and angiogenesis via upregulating HOTTIP and activating HIF-1α/VEGF signaling[J].Cell Death and Disease,2022,13(2):102-115.DOI:10.1038/s41419-022-04505-5.